Editas Medicine, Inc.EDIT
What Editas Medicine, Inc. does.
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.
We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. Once the complex binds to the DNA sequence it is designed to recognize, the complex makes a specific cut in the DNA. We believe we are the only human gene editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both of these CRISPR systems, and foundational intellectual property for both of these CRISPR systems. Because of the broad nature of this platform, we believe we can create gene editing molecules for more than 95% of the human genome.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Net income | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| Free cash flow | -$187.0M | -$171.8M | -$181.5M | -$136.9M | -$219.1M | -$165.8M |
More on EDIT.
- Editas Medicine, Inc. summary
- Editas Medicine, Inc. financial statements
- Editas Medicine, Inc. key metrics
- Editas Medicine, Inc. health scores and style box
- Editas Medicine, Inc. earnings
- Editas Medicine, Inc. dividends
- Editas Medicine, Inc. valuation
- Editas Medicine, Inc. ownership and insiders
- Editas Medicine, Inc. peers
Figures from Editas Medicine, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.